Human studies indicate that circulating levels of FGF21 increased in obese individuals [18], subjects with metabolic syndrome, type 2 diabetes mellitus[19]–[21] and coronary heart disease[22]. This evidence concerns the gene FGF21 and coronary artery disorder.